GSK Abreva Performance Claims Affirmed By NAD, Leave Novartis Sore
This article was originally published in The Tan Sheet
Executive Summary
Advertising claims that GlaxoSmithKline's cold-sore treatment Abreva "speeds healing like a prescription without one" are supported, the National Advertising Division of the Council of Better Business Bureaus concludes after a recent inquiry
You may also be interested in...
Merix/Glaxo Cold Sore Cold War Ends With Settlement
The cold sore treatment cold war between competing manufacturers Merix Pharmaceutical Corp. and GlaxoSmithKline ended this month when the firms settled their multi-court false advertising dispute after more than four years of litigation
Abreva Shortened Healing Time, Duration Of Cold Sores Stressed In Promos
SmithKline Beecham's Abreva, now hitting shelves in food, drug and mass outlets, is the first OTC indicated for shortening the healing time and duration of symptoms related to cold sores and fever blisters.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC